Literature DB >> 30892981

External validation of prognostic models for preeclampsia in a Dutch multicenter prospective cohort.

Marije Lamain-de Ruiter1, Anneke Kwee1, Christiana A Naaktgeboren2, Rebecca D Louhanepessy3, Inge De Groot4, Inge M Evers5, Floris Groenendaal6, Yolanda R Hering7, Anjoke J M Huisjes8, Cornel Kirpestein9, Wilma M Monincx10, Peter C J I Schielen11, Annewil Van 't Zelfde12, Charlotte M Van Oirschot13, Simone A Vankan-Buitelaar14, Mariska A A W Vonk15, Therese A Wiegers16, Joost J Zwart17, Karel G M Moons2, Arie Franx1, Maria P H Koster1,18.   

Abstract

OBJECTIVE: To perform an external validation of all published prognostic models for first-trimester prediction of the risk of developing preeclampsia (PE).
METHODS: Women <14 weeks of pregnancy were recruited in the Netherlands. All systematically identified prognostic models for PE that contained predictors commonly available were eligible for external validation.
RESULTS: 3,736 women were included; 87 (2.3%) developed PE. Calibration was poor due to overestimation. Discrimination of 9 models for LO-PE ranged from 0.58 to 0.71 and of 9 models for all PE from 0.55 to 0.75.
CONCLUSION: Only a few easily applicable prognostic models for all PE showed discrimination above 0.70, which is considered an acceptable performance.

Entities:  

Keywords:  First trimester; external validation; preeclampsia; prognostic model

Mesh:

Year:  2019        PMID: 30892981     DOI: 10.1080/10641955.2019.1584210

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  7 in total

Review 1.  Comparative risks and predictors of preeclamptic pregnancy in the Eastern, Western and developing world.

Authors:  Ning Zhang; Jing Tan; HaiFeng Yang; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2020-09-25       Impact factor: 5.858

2.  Low fetal fraction in cell-free DNA testing is associated with adverse pregnancy outcome: Analysis of a subcohort of the TRIDENT-2 study.

Authors:  Ellis C Becking; Soetinah A M Wirjosoekarto; Peter G Scheffer; Julia V M Huiskes; Marinka J Remmelink; Erik A Sistermans; Caroline J Bax; Janneke M Weiss; Lidewij Henneman; Mireille N Bekker
Journal:  Prenat Diagn       Date:  2021-09-09       Impact factor: 3.242

3.  Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test.

Authors:  Louise C Kenny; Grégoire Thomas; Lucilla Poston; Jenny E Myers; Nigel A B Simpson; Fergus P McCarthy; Leslie W Brown; Alison E Bond; Robin Tuytten; Philip N Baker
Journal:  PLoS One       Date:  2020-12-28       Impact factor: 3.240

4.  Associations between periconceptional lifestyle behaviours and adverse pregnancy outcomes.

Authors:  Veronique Y F Maas; Marjolein Poels; Marije Lamain-de Ruiter; Anneke Kwee; Mireille N Bekker; Arie Franx; Maria P H Koster
Journal:  BMC Pregnancy Childbirth       Date:  2021-07-07       Impact factor: 3.007

5.  Study protocol for a prospective cohort study to investigate Hemodynamic Adaptation to Pregnancy and Placenta-related Outcome: the HAPPO study.

Authors:  Rianne C Bijl; Jérôme M J Cornette; Annemien E van den Bosch; Johannes J Duvekot; Jeroen Molinger; Sten P Willemsen; Anton H J Koning; Jolien W Roos-Hesselink; Arie Franx; Régine P M Steegers-Theunissen; Maria P H Koster
Journal:  BMJ Open       Date:  2019-11-10       Impact factor: 2.692

6.  Home-Based Monitoring and Telemonitoring of Complicated Pregnancies: Nationwide Cross-Sectional Survey of Current Practice in the Netherlands.

Authors:  Josephus F M van den Heuvel; Samira Ayubi; Arie Franx; Mireille N Bekker
Journal:  JMIR Mhealth Uhealth       Date:  2020-10-28       Impact factor: 4.773

7.  Prognostic models versus single risk factor approach in first-trimester selective screening for gestational diabetes mellitus: a prospective population-based multicentre cohort study.

Authors:  F van Hoorn; Mph Koster; C A Naaktgeboren; F Groenendaal; A Kwee; M Lamain-de Ruiter; A Franx; M N Bekker
Journal:  BJOG       Date:  2020-09-01       Impact factor: 6.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.